disc-0974
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 10, 2021 (NCT04999527)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- HemojuvelinANTAGONIST
HJV antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05745883 | Phase 1 | Apr 4, 2023 | Disc Medicine, Inc |
| NCT05320198 | Phase 1/Phase 2 (Phase 2) | Jun 6, 2022 | Disc Medicine, Inc |
| NCT04999527 | Phase 1 | Aug 10, 2021 | Disc Medicine, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Disc Medicine, Inc | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1